Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprocitentan in Resistant Hypertension
NCT07635914Phase 3Not yet recruiting
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- May 2026
- Primary completion
- Dec 2029
01
Overview
A Phase 3 trial of aprocitentan in resistant hypertension (RH), sponsored by CSPC Zhongnuo Pharmaceutical. Planned start May 2026; status: not yet recruiting.
02
Drugs
aprocitentan
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NCT07635914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07635914.